Aditxt, Inc.

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, NVO has a market cap of 198B. Regarding current trading prices, ADTX is priced at $0.20, while NVO trades at $44.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas NVO's P/E ratio is 10.46. In terms of profitability, ADTX's ROE is +9.26%, compared to NVO's ROE of +0.66%. Regarding short-term risk, ADTX is more volatile compared to NVO. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check NVO's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, VRTX has a market cap of 111B. Regarding current trading prices, ADTX is priced at $0.20, while VRTX trades at $437.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas VRTX's P/E ratio is 25.92. In terms of profitability, ADTX's ROE is +9.26%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, ADTX is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check VRTX's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, ADTX is priced at $0.20, while VRNA trades at $106.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas VRNA's P/E ratio is -102.80. In terms of profitability, ADTX's ROE is +9.26%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, ADTX is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check VRNA's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, REGN has a market cap of 64.7B. Regarding current trading prices, ADTX is priced at $0.20, while REGN trades at $627.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas REGN's P/E ratio is 15.33. In terms of profitability, ADTX's ROE is +9.26%, compared to REGN's ROE of +0.14%. Regarding short-term risk, ADTX is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check REGN's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, ARGX has a market cap of 50.8B. Regarding current trading prices, ADTX is priced at $0.20, while ARGX trades at $820.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas ARGX's P/E ratio is 36.47. In terms of profitability, ADTX's ROE is +9.26%, compared to ARGX's ROE of +0.37%. Regarding short-term risk, ADTX is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check ARGX's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ADTX is priced at $0.20, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ADTX's ROE is +9.26%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ADTX is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check SGEN's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, ALNY has a market cap of 39.5B. Regarding current trading prices, ADTX is priced at $0.20, while ALNY trades at $295.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas ALNY's P/E ratio is 74.09. In terms of profitability, ADTX's ROE is +9.26%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, ADTX is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check ALNY's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, RVMD has a market cap of 32.5B. Regarding current trading prices, ADTX is priced at $0.20, while RVMD trades at $153.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas RVMD's P/E ratio is -21.52. In terms of profitability, ADTX's ROE is +9.26%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, ADTX is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check RVMD's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, UTHR has a market cap of 24.2B. Regarding current trading prices, ADTX is priced at $0.20, while UTHR trades at $570.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas UTHR's P/E ratio is 21.09. In terms of profitability, ADTX's ROE is +9.26%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, ADTX is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check UTHR's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, BNTX has a market cap of 23.5B. Regarding current trading prices, ADTX is priced at $0.20, while BNTX trades at $93.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas BNTX's P/E ratio is -15.76. In terms of profitability, ADTX's ROE is +9.26%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, ADTX is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check BNTX's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, RPRX has a market cap of 23.2B. Regarding current trading prices, ADTX is priced at $0.20, while RPRX trades at $53.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas RPRX's P/E ratio is 28.41. In terms of profitability, ADTX's ROE is +9.26%, compared to RPRX's ROE of +0.13%. Regarding short-term risk, ADTX is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check RPRX's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, INSM has a market cap of 23.1B. Regarding current trading prices, ADTX is priced at $0.20, while INSM trades at $106.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas INSM's P/E ratio is -18.47. In terms of profitability, ADTX's ROE is +9.26%, compared to INSM's ROE of -1.30%. Regarding short-term risk, ADTX is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check INSM's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, ROIV has a market cap of 21.3B. Regarding current trading prices, ADTX is priced at $0.20, while ROIV trades at $29.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas ROIV's P/E ratio is -54.78. In terms of profitability, ADTX's ROE is +9.26%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, ADTX is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check ROIV's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ADTX is priced at $0.20, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ADTX's ROE is +9.26%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, ADTX is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check BGNE's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, INCY has a market cap of 19.4B. Regarding current trading prices, ADTX is priced at $0.20, while INCY trades at $97.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas INCY's P/E ratio is 13.75. In terms of profitability, ADTX's ROE is +9.26%, compared to INCY's ROE of +0.29%. Regarding short-term risk, ADTX is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check INCY's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, MRNA has a market cap of 18.9B. Regarding current trading prices, ADTX is priced at $0.20, while MRNA trades at $47.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas MRNA's P/E ratio is -5.85. In terms of profitability, ADTX's ROE is +9.26%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, ADTX is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check MRNA's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ADTX is priced at $0.20, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ADTX's ROE is +9.26%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, ADTX is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check DNA-WT's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, GMAB has a market cap of 16.4B. Regarding current trading prices, ADTX is priced at $0.20, while GMAB trades at $26.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas GMAB's P/E ratio is 20.39. In terms of profitability, ADTX's ROE is +9.26%, compared to GMAB's ROE of +0.21%. Regarding short-term risk, ADTX is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check GMAB's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, NBIX has a market cap of 15.7B. Regarding current trading prices, ADTX is priced at $0.20, while NBIX trades at $155.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas NBIX's P/E ratio is 23.97. In terms of profitability, ADTX's ROE is +9.26%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, ADTX is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check NBIX's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, JAZZ has a market cap of 14.9B. Regarding current trading prices, ADTX is priced at $0.20, while JAZZ trades at $237.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas JAZZ's P/E ratio is 1981.83. In terms of profitability, ADTX's ROE is +9.26%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, ADTX is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check JAZZ's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, ASND has a market cap of 14.5B. Regarding current trading prices, ADTX is priced at $0.20, while ASND trades at $235.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas ASND's P/E ratio is 26.76. In terms of profitability, ADTX's ROE is +9.26%, compared to ASND's ROE of -56.42%. Regarding short-term risk, ADTX is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check ASND's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, SMMT has a market cap of 13.5B. Regarding current trading prices, ADTX is priced at $0.20, while SMMT trades at $17.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas SMMT's P/E ratio is -10.92. In terms of profitability, ADTX's ROE is +9.26%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, ADTX is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check SMMT's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, BBIO has a market cap of 13B. Regarding current trading prices, ADTX is priced at $0.20, while BBIO trades at $66.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas BBIO's P/E ratio is -17.76. In terms of profitability, ADTX's ROE is +9.26%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, ADTX is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check BBIO's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, IONS has a market cap of 12.6B. Regarding current trading prices, ADTX is priced at $0.20, while IONS trades at $76.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas IONS's P/E ratio is -38.05. In terms of profitability, ADTX's ROE is +9.26%, compared to IONS's ROE of -0.59%. Regarding short-term risk, ADTX is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check IONS's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ADTX is priced at $0.20, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ADTX's ROE is +9.26%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ADTX is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check KRTX's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, EXEL has a market cap of 12.6B. Regarding current trading prices, ADTX is priced at $0.20, while EXEL trades at $50.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas EXEL's P/E ratio is 16.57. In terms of profitability, ADTX's ROE is +9.26%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, ADTX is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check EXEL's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, MDGL has a market cap of 12.2B. Regarding current trading prices, ADTX is priced at $0.20, while MDGL trades at $527.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas MDGL's P/E ratio is -39.06. In terms of profitability, ADTX's ROE is +9.26%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, ADTX is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check MDGL's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, AXSM has a market cap of 12.1B. Regarding current trading prices, ADTX is priced at $0.20, while AXSM trades at $234.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas AXSM's P/E ratio is -63.04. In terms of profitability, ADTX's ROE is +9.26%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, ADTX is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check AXSM's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, ADTX is priced at $0.20, while RNAM trades at $72.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas RNAM's P/E ratio is -17.39. In terms of profitability, ADTX's ROE is +9.26%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, ADTX is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check RNAM's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, ARWR has a market cap of 11.1B. Regarding current trading prices, ADTX is priced at $0.20, while ARWR trades at $78.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas ARWR's P/E ratio is -34.80. In terms of profitability, ADTX's ROE is +9.26%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, ADTX is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check ARWR's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, BMRN has a market cap of 10.1B. Regarding current trading prices, ADTX is priced at $0.20, while BMRN trades at $52.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas BMRN's P/E ratio is 37.68. In terms of profitability, ADTX's ROE is +9.26%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, ADTX is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check BMRN's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, CYTK has a market cap of 9.6B. Regarding current trading prices, ADTX is priced at $0.20, while CYTK trades at $77.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas CYTK's P/E ratio is -11.26. In terms of profitability, ADTX's ROE is +9.26%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, ADTX is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check CYTK's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ADTX is priced at $0.20, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ADTX's ROE is +9.26%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ADTX is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check RXDX's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, KRYS has a market cap of 9B. Regarding current trading prices, ADTX is priced at $0.20, while KRYS trades at $306.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas KRYS's P/E ratio is 40.94. In terms of profitability, ADTX's ROE is +9.26%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, ADTX is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check KRYS's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ADTX is priced at $0.20, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ADTX's ROE is +9.26%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, ADTX is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check IMGN's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, ABVX has a market cap of 8.5B. Regarding current trading prices, ADTX is priced at $0.20, while ABVX trades at $129.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas ABVX's P/E ratio is -24.20. In terms of profitability, ADTX's ROE is +9.26%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, ADTX is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check ABVX's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ADTX is priced at $0.20, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ADTX's ROE is +9.26%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, ADTX is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check BPMC's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, IBRX has a market cap of 8.3B. Regarding current trading prices, ADTX is priced at $0.20, while IBRX trades at $7.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas IBRX's P/E ratio is -9.28. In terms of profitability, ADTX's ROE is +9.26%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, ADTX is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check IBRX's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ADTX is priced at $0.20, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas CERE's P/E ratio is -16.47. In terms of profitability, ADTX's ROE is +9.26%, compared to CERE's ROE of -0.72%. Regarding short-term risk, ADTX is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check CERE's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, HALO has a market cap of 8.1B. Regarding current trading prices, ADTX is priced at $0.20, while HALO trades at $68.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas HALO's P/E ratio is 24.09. In terms of profitability, ADTX's ROE is +9.26%, compared to HALO's ROE of +1.26%. Regarding short-term risk, ADTX is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check HALO's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, NUVL has a market cap of 7.9B. Regarding current trading prices, ADTX is priced at $0.20, while NUVL trades at $107.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas NUVL's P/E ratio is -17.72. In terms of profitability, ADTX's ROE is +9.26%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, ADTX is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check NUVL's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, PRAX has a market cap of 7.6B. Regarding current trading prices, ADTX is priced at $0.20, while PRAX trades at $357.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas PRAX's P/E ratio is -26.69. In terms of profitability, ADTX's ROE is +9.26%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, ADTX is more volatile compared to PRAX. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check PRAX's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, TECH has a market cap of 7.5B. Regarding current trading prices, ADTX is priced at $0.20, while TECH trades at $48.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas TECH's P/E ratio is 68.70. In terms of profitability, ADTX's ROE is +9.26%, compared to TECH's ROE of +0.05%. Regarding short-term risk, ADTX is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check TECH's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, ADTX is priced at $0.20, while MTSR trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas MTSR's P/E ratio is -23.58. In terms of profitability, ADTX's ROE is +9.26%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, ADTX is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check MTSR's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, PCVX has a market cap of 7.4B. Regarding current trading prices, ADTX is priced at $0.20, while PCVX trades at $51.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas PCVX's P/E ratio is -7.40. In terms of profitability, ADTX's ROE is +9.26%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, ADTX is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check PCVX's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, CORT has a market cap of 7.2B. Regarding current trading prices, ADTX is priced at $0.20, while CORT trades at $66.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas CORT's P/E ratio is 190.51. In terms of profitability, ADTX's ROE is +9.26%, compared to CORT's ROE of +0.08%. Regarding short-term risk, ADTX is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check CORT's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, IMVT has a market cap of 6.9B. Regarding current trading prices, ADTX is priced at $0.20, while IMVT trades at $33.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas IMVT's P/E ratio is -12.06. In terms of profitability, ADTX's ROE is +9.26%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, ADTX is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check IMVT's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, ADTX is priced at $0.20, while MRUS trades at $90.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas MRUS's P/E ratio is -17.05. In terms of profitability, ADTX's ROE is +9.26%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, ADTX is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check MRUS's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, ADTX is priced at $0.20, while ACLX trades at $115.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas ACLX's P/E ratio is -28.27. In terms of profitability, ADTX's ROE is +9.26%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, ADTX is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check ACLX's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, KYMR has a market cap of 6.7B. Regarding current trading prices, ADTX is priced at $0.20, while KYMR trades at $81.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas KYMR's P/E ratio is -22.28. In terms of profitability, ADTX's ROE is +9.26%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, ADTX is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check KYMR's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, PTGX has a market cap of 6.6B. Regarding current trading prices, ADTX is priced at $0.20, while PTGX trades at $102.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas PTGX's P/E ratio is -56.47. In terms of profitability, ADTX's ROE is +9.26%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, ADTX is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check PTGX's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ADTX is priced at $0.20, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas RETA's P/E ratio is -66.29. In terms of profitability, ADTX's ROE is +9.26%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ADTX is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check RETA's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, CELC has a market cap of 6.5B. Regarding current trading prices, ADTX is priced at $0.20, while CELC trades at $133.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas CELC's P/E ratio is -34.43. In terms of profitability, ADTX's ROE is +9.26%, compared to CELC's ROE of -2.45%. Regarding short-term risk, ADTX is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check CELC's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, ALKS has a market cap of 6.4B. Regarding current trading prices, ADTX is priced at $0.20, while ALKS trades at $38.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas ALKS's P/E ratio is 42.34. In terms of profitability, ADTX's ROE is +9.26%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, ADTX is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check ALKS's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, RYTM has a market cap of 6.3B. Regarding current trading prices, ADTX is priced at $0.20, while RYTM trades at $91.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas RYTM's P/E ratio is -29.21. In terms of profitability, ADTX's ROE is +9.26%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, ADTX is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check RYTM's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, CNTA has a market cap of 6.2B. Regarding current trading prices, ADTX is priced at $0.20, while CNTA trades at $39.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas CNTA's P/E ratio is -22.34. In terms of profitability, ADTX's ROE is +9.26%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, ADTX is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check CNTA's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, SRRK has a market cap of 6.1B. Regarding current trading prices, ADTX is priced at $0.20, while SRRK trades at $50.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas SRRK's P/E ratio is -14.68. In terms of profitability, ADTX's ROE is +9.26%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, ADTX is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check SRRK's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, TGTX has a market cap of 6B. Regarding current trading prices, ADTX is priced at $0.20, while TGTX trades at $39.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas TGTX's P/E ratio is 13.71. In terms of profitability, ADTX's ROE is +9.26%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, ADTX is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check TGTX's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, COGT has a market cap of 5.9B. Regarding current trading prices, ADTX is priced at $0.20, while COGT trades at $34.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas COGT's P/E ratio is -15.90. In terms of profitability, ADTX's ROE is +9.26%, compared to COGT's ROE of -0.83%. Regarding short-term risk, ADTX is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check COGT's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, PTCT has a market cap of 5.9B. Regarding current trading prices, ADTX is priced at $0.20, while PTCT trades at $70.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas PTCT's P/E ratio is -27.82. In terms of profitability, ADTX's ROE is +9.26%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, ADTX is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check PTCT's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, BLTE has a market cap of 5.7B. Regarding current trading prices, ADTX is priced at $0.20, while BLTE trades at $142.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas BLTE's P/E ratio is -55.92. In terms of profitability, ADTX's ROE is +9.26%, compared to BLTE's ROE of -0.27%. Regarding short-term risk, ADTX is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check BLTE's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, ADTX is priced at $0.20, while CDTX trades at $221.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas CDTX's P/E ratio is -19.77. In terms of profitability, ADTX's ROE is +9.26%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, ADTX is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check CDTX's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ADTX is priced at $0.20, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ADTX's ROE is +9.26%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ADTX is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check ABCM's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, LQDA has a market cap of 5.5B. Regarding current trading prices, ADTX is priced at $0.20, while LQDA trades at $62.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas LQDA's P/E ratio is 364.85. In terms of profitability, ADTX's ROE is +9.26%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, ADTX is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check LQDA's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ADTX is priced at $0.20, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ADTX's ROE is +9.26%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ADTX is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check ISEE's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, CGON has a market cap of 5.4B. Regarding current trading prices, ADTX is priced at $0.20, while CGON trades at $60.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas CGON's P/E ratio is -25.98. In terms of profitability, ADTX's ROE is +9.26%, compared to CGON's ROE of -0.23%. Regarding short-term risk, ADTX is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check CGON's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, LEGN has a market cap of 5.3B. Regarding current trading prices, ADTX is priced at $0.20, while LEGN trades at $28.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas LEGN's P/E ratio is -20.65. In terms of profitability, ADTX's ROE is +9.26%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, ADTX is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check LEGN's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, ADTX is priced at $0.20, while APLS trades at $41.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas APLS's P/E ratio is 38.35. In terms of profitability, ADTX's ROE is +9.26%, compared to APLS's ROE of +0.40%. Regarding short-term risk, ADTX is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check APLS's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, FBIOX has a market cap of 5.2B. Regarding current trading prices, ADTX is priced at $0.20, while FBIOX trades at $25.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas FBIOX's P/E ratio is N/A. In terms of profitability, ADTX's ROE is +9.26%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, ADTX is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check FBIOX's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, CRSP has a market cap of 5.2B. Regarding current trading prices, ADTX is priced at $0.20, while CRSP trades at $53.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas CRSP's P/E ratio is -8.68. In terms of profitability, ADTX's ROE is +9.26%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, ADTX is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check CRSP's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, MIRM has a market cap of 4.9B. Regarding current trading prices, ADTX is priced at $0.20, while MIRM trades at $97.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas MIRM's P/E ratio is -7.16. In terms of profitability, ADTX's ROE is +9.26%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, ADTX is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check MIRM's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, APGE has a market cap of 4.8B. Regarding current trading prices, ADTX is priced at $0.20, while APGE trades at $77.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas APGE's P/E ratio is -17.96. In terms of profitability, ADTX's ROE is +9.26%, compared to APGE's ROE of -0.33%. Regarding short-term risk, ADTX is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check APGE's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, ADTX is priced at $0.20, while TERN trades at $52.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas TERN's P/E ratio is -51.41. In terms of profitability, ADTX's ROE is +9.26%, compared to TERN's ROE of -0.20%. Regarding short-term risk, ADTX is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check TERN's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, LGND has a market cap of 4.7B. Regarding current trading prices, ADTX is priced at $0.20, while LGND trades at $235.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas LGND's P/E ratio is 30.74. In terms of profitability, ADTX's ROE is +9.26%, compared to LGND's ROE of +0.16%. Regarding short-term risk, ADTX is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check LGND's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, ADTX is priced at $0.20, while FOLD trades at $14.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas FOLD's P/E ratio is -161.00. In terms of profitability, ADTX's ROE is +9.26%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, ADTX is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check FOLD's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, ADTX is priced at $0.20, while AKRO trades at $54.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas AKRO's P/E ratio is -14.57. In terms of profitability, ADTX's ROE is +9.26%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, ADTX is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check AKRO's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, ADTX is priced at $0.20, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ADTX's ROE is +9.26%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, ADTX is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check ALPN's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, TVTX has a market cap of 4.4B. Regarding current trading prices, ADTX is priced at $0.20, while TVTX trades at $47.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas TVTX's P/E ratio is -95.52. In terms of profitability, ADTX's ROE is +9.26%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, ADTX is more volatile compared to TVTX. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check TVTX's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, SYRE has a market cap of 4.4B. Regarding current trading prices, ADTX is priced at $0.20, while SYRE trades at $72.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas SYRE's P/E ratio is -34.20. In terms of profitability, ADTX's ROE is +9.26%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, ADTX is more volatile compared to SYRE. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check SYRE's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, CAI has a market cap of 4.3B. Regarding current trading prices, ADTX is priced at $0.20, while CAI trades at $15.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas CAI's P/E ratio is -5.57. In terms of profitability, ADTX's ROE is +9.26%, compared to CAI's ROE of +0.06%. Regarding short-term risk, ADTX is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check CAI's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, NAMS has a market cap of 4.3B. Regarding current trading prices, ADTX is priced at $0.20, while NAMS trades at $36.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas NAMS's P/E ratio is -20.54. In terms of profitability, ADTX's ROE is +9.26%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, ADTX is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check NAMS's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, XENE has a market cap of 4.3B. Regarding current trading prices, ADTX is priced at $0.20, while XENE trades at $53.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas XENE's P/E ratio is -11.47. In terms of profitability, ADTX's ROE is +9.26%, compared to XENE's ROE of -0.49%. Regarding short-term risk, ADTX is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check XENE's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ADTX is priced at $0.20, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas OPT's P/E ratio is -1.52. In terms of profitability, ADTX's ROE is +9.26%, compared to OPT's ROE of +0.88%. Regarding short-term risk, ADTX is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check OPT's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, MANE has a market cap of 4.2B. Regarding current trading prices, ADTX is priced at $0.20, while MANE trades at $100.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas MANE's P/E ratio is -37.84. In terms of profitability, ADTX's ROE is +9.26%, compared to MANE's ROE of -0.95%. Regarding short-term risk, ADTX is more volatile compared to MANE. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check MANE's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ADTX is priced at $0.20, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ADTX's ROE is +9.26%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ADTX is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check MRTX's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, KNSA has a market cap of 3.9B. Regarding current trading prices, ADTX is priced at $0.20, while KNSA trades at $51.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas KNSA's P/E ratio is 56.94. In terms of profitability, ADTX's ROE is +9.26%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, ADTX is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check KNSA's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, CRNX has a market cap of 3.9B. Regarding current trading prices, ADTX is priced at $0.20, while CRNX trades at $36.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas CRNX's P/E ratio is -7.16. In terms of profitability, ADTX's ROE is +9.26%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, ADTX is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check CRNX's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, ERAS has a market cap of 3.9B. Regarding current trading prices, ADTX is priced at $0.20, while ERAS trades at $12.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas ERAS's P/E ratio is -13.41. In terms of profitability, ADTX's ROE is +9.26%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, ADTX is more volatile compared to ERAS. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check ERAS's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, CPRX has a market cap of 3.8B. Regarding current trading prices, ADTX is priced at $0.20, while CPRX trades at $31.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas CPRX's P/E ratio is 18.10. In terms of profitability, ADTX's ROE is +9.26%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, ADTX is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check CPRX's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, ADTX is priced at $0.20, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas RYZB's P/E ratio is -57.86. In terms of profitability, ADTX's ROE is +9.26%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, ADTX is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check RYZB's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, ADTX is priced at $0.20, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas CBAY's P/E ratio is -32.81. In terms of profitability, ADTX's ROE is +9.26%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, ADTX is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check CBAY's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, VKTX has a market cap of 3.7B. Regarding current trading prices, ADTX is priced at $0.20, while VKTX trades at $31.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas VKTX's P/E ratio is -7.63. In terms of profitability, ADTX's ROE is +9.26%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, ADTX is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check VKTX's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, ACAD has a market cap of 3.6B. Regarding current trading prices, ADTX is priced at $0.20, while ACAD trades at $21.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas ACAD's P/E ratio is 9.58. In terms of profitability, ADTX's ROE is +9.26%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, ADTX is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check ACAD's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, DNTH has a market cap of 3.6B. Regarding current trading prices, ADTX is priced at $0.20, while DNTH trades at $86.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas DNTH's P/E ratio is -20.49. In terms of profitability, ADTX's ROE is +9.26%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, ADTX is more volatile compared to DNTH. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check DNTH's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, EWTX has a market cap of 3.6B. Regarding current trading prices, ADTX is priced at $0.20, while EWTX trades at $33.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas EWTX's P/E ratio is -20.20. In terms of profitability, ADTX's ROE is +9.26%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, ADTX is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check EWTX's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, VCYT has a market cap of 3.5B. Regarding current trading prices, ADTX is priced at $0.20, while VCYT trades at $44.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas VCYT's P/E ratio is 41.19. In terms of profitability, ADTX's ROE is +9.26%, compared to VCYT's ROE of +0.07%. Regarding short-term risk, ADTX is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check VCYT's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, ADTX is priced at $0.20, while SWTX trades at $46.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas SWTX's P/E ratio is -13.78. In terms of profitability, ADTX's ROE is +9.26%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, ADTX is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check SWTX's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, TLX has a market cap of 3.3B. Regarding current trading prices, ADTX is priced at $0.20, while TLX trades at $9.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas TLX's P/E ratio is -487.00. In terms of profitability, ADTX's ROE is +9.26%, compared to TLX's ROE of -0.02%. Regarding short-term risk, ADTX is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check TLX's competition here

ADTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ADTX stands at 6.9K. In comparison, BEAM has a market cap of 3.3B. Regarding current trading prices, ADTX is priced at $0.20, while BEAM trades at $31.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ADTX currently has a P/E ratio of N/A, whereas BEAM's P/E ratio is -65.08. In terms of profitability, ADTX's ROE is +9.26%, compared to BEAM's ROE of -0.06%. Regarding short-term risk, ADTX is more volatile compared to BEAM. This indicates potentially higher risk in terms of short-term price fluctuations for ADTX.Check BEAM's competition here